ArticleHypertension research : official journal of the Japanese Society of Hypertension2022
Blood pressure, frailty status, and all-cause mortality in elderly hypertensives; The Nambu Cohort Study.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Frailty and blood pressure in older adults: rethinking risk and treatment strategies.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Blood pressure satisfaction and antihypertensive medication adherence effects frailty transitions in older hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Frailty and Cardiovascular Risk.European cardiology · 2026Review
- Body mass index and sarcopenia and mortality risk among older hypertensive outpatients; the Nambu Cohort Study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- The relationship between frailty syndrome and quality of life in patients with hypertension: a multidimensional analysis.BMC geriatrics · 2025Article
- Pulse pressure tells the story of sarcopenia.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Current issues in frailty and hypertension management.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Current topics of frailty in association with hypertension and other medical conditions.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Elevated pulse pressure and cardiovascular risk associated in Spanish population attended in primary care: IBERICAN study.Frontiers in cardiovascular medicine · 2023Article
- Insufficient blood pressure control is independently associated with increased arterial stiffness.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Update on Hypertension Research in 2021.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Prognostic significance of blood pressure in frail older adults.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Systolic Blood Pressure and Mortality in Community-Dwelling Older Adults: The Role of Frailty.The journal of nutrition, health & aging · 2022Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antihypertensive therapy is pivotal for reducing cardiovascular events. The 2019 Guidelines for the Management of Hypertension set a target blood pressure (BP) of <140/90 mmHg for persons older than 75 years of age. Optimal BP levels for older persons with frailty, however, are controversial because evidence for the relationship between BP level and prognosis by frailty status is limited. Here, we evaluated the relationship between systolic BP and frailty status with all-cause mortality in ambulatory older hypertensive patients using data from the Nambu Cohort study. A total of 535 patients (age 78 [70-84] years, 51% men, 37% with frailty) were prospectively followed for a mean duration of 41 (34-43) months. During the follow-up period, 49 patients died. Mortality rates stratified by systolic BP and frailty status were lowest in patients with systolic BP < 140 mmHg and non-frailty, followed by those with systolic BP ≥ 140 mmHg and non-frailty. Patients with frailty had the highest mortality regardless of the BP level. The adjusted hazard ratios (95% confidence intervals) of each category for all-cause mortality were as follows: ≥140 mmHg/Non-frailty 3.19 (1.12-11.40), <140 mmHg/Frailty 4.72 (1.67-16.90), and ≥140 mmHg/Frailty 3.56 (1.16-13.40) compared with <140 mmHg/Non-frailty as a reference. These results indicated that frail patients have a poor prognosis regardless of their BP levels. Non-frail patients, however, with systolic BP levels <140 mmHg had a better prognosis. Frailty may be a marker to differentiate patients who are likely to gain benefit from antihypertensive medication among older hypertensives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.